Skip to main content

Mental Health News

News
There is very little evidence supporting the treatment of mental health disorders with cannabis, according to the results of a recent meta-analysis. Although it has been suggested that cannabinoids and their synthetic derivatives could be used for the treatment of mental health disorders, their…
News
A high-salt diet affects endothelial dysfunction and tau regulation in the brain, according to new research being presented at the 144th Annual Meeting of the American Neurological Association. While it is well known that salt intake is associated with poor vascular outcomes, including stroke and…
News
American Health Packaging is recalling a single lot of carbamazepine tablets because samples failed to meet dissolution specifications during routine testing. The recall was announced in the August 21, 2019, US Food and Drug Administration (FDA) Enforcement Report.  The recall affects 10-dose…
News
The American Academy of Neurology (AAN) and American Headache Society (AHS) have published updated guidelines on the prevention and treatment of migraine in children and adolescents. In the guidelines, the authors highlight that a key component in preventing and treating migraine is maintaining a…
News
High intake of caffeine may be a trigger for migraine on the following day, according to results of a new study. To come to this conclusion, the researchers prospectively studied 98 adults with episodic migraine who completed electronic diary entries for at least 6 weeks. In these entries,…
News
By Manojna Maddipatla (Reuters) - Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of a late-stage study in patients with major depressive episodes associated with bipolar disorder. The treatment, lumateperone, which is being studied as a monotherapy for the…
News
According to a recent warning from the FDA, patients with multiple sclerosis (MS) will experience severe worsening of the disease if they stop treatment with Gilenya (fingolimod; Novarits). The FDA explained, “This MS worsening is rare but can result in permanent disability.” “FDA is warning that…
News
By Saumya Joseph (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc's treatment for depression in patients with an inadequate response to standard antidepressant therapies. The decision comes two days after FDA staff reviewers…
News
By Will Boggs MD NEW YORK (Reuters Health) - Antidepressants provide little relief for depressed people with dementia, according to a systematic review. "Studies that have come out in recent years all pointed toward the same conclusion," Dr. Robert Dudas from the University of Cambridge, in the U…
News
By Reuters Staff (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG’s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents. MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts…
Back to Top